After tumor progression, repeated molecular pathology revealed the BRAF V600E mutation in an almost unaltered frequency (from 6% to 2.5%), so that there was no indication of preferential growth of the BRAF-mutated clone. This evidence concerns the gene BRAF and neoplasm.